Quinoline derivative for treating rheumatoid arthritis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rheumatoid arthritis, such as traditional synthetic DMARDs and glucocorticoids, are costly and have significant side effects, while biological DMARDs are expensive and may lead to relapse or aggravate disease development, and none can prevent disease progression.
Innovation Solution
Administration of a quinoline derivative, specifically 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine, or its pharmaceutically acceptable salts, alone or in combination with other DMARDs, to treat rheumatoid arthritis, improving physical function and quality of life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional synthetic DMARDs (methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) are used to treat rheumatoid arthritis, then disease progression can be slowed and joints protected from permanent damage, but significant side effects occur including liver damage, bone marrow suppression, and serious lung infections
Solution Approach 1:
The patent introduces a novel chemical compound (quinoline derivative with specific molecular structure) that changes the pharmacological parameters of treatment. This new compound aims to achieve similar or better disease control while modifying the safety profile by reducing hepatotoxicity, bone marrow suppression, and pulmonary toxicity associated with traditional DMARDs
2Reliability
If targeted synthetic DMARDs and biological DMARDs are used to treat rheumatoid arthritis, then treatment effectiveness is improved, but treatment cost increases significantly
Solution Approach 1:
The patent presents a small molecule quinoline derivative that can be synthesized cost-effectively compared to expensive biological DMARDs. This approach uses a chemically synthesizable compound rather than complex biologic products, aiming to provide effective treatment at a lower cost burden for patients
3Ease of operation
If glucocorticoids are used alone or in large doses over a long period to control RA symptoms, then rapid symptom relief is achieved, but disease relapse occurs and disease development is aggravated
Solution Approach 1:
The patent introduces the quinoline derivative as an intermediary therapeutic agent that can control disease progression and symptoms without the harmful rebound effects of glucocorticoids. This new compound acts as a mediator between symptomatic relief and disease modification, aiming to provide sustained benefit without aggravating disease development upon withdrawal
Data Source
AI summary
A quinoline derivative for treating rheumatoid arthritis and a use thereof in preparing a pharmaceutical composition for treating rheumatoid arthritis. In particular, a use of the quinoline derivative 1-[[[4-(4-Fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropanamine in treating rheumatoid arthritis.